DI-098 Consolidation of radipharmaceutical 99mtc-edda/hynic-toc in imaging tests for diagnosis of neuroendocrine tumours

    loading  Checking for direct PDF access through Ovid



Neuroendocrine tumours (NET) overexpress somatostatin receptors on cell membranes. Imaging tests with somatostatin analogue tracers (SAT) are used for diagnosis and follow-up of NET and their metastases. Current guidelines recommend 111 In(DTPA)-octreotide for this use but new alternatives are available, such as 99mTc-labelled SAT.


To study the consolidation of 99mTc-EDDA/HYNIC-TOC (99mTc-Tektrotyd) as SAT for the diagnose of NET in our centre.

Material and methods

We analysed the requests for 99mTc-Tektrotyd received from the nuclear medicine service from November 2015 to September 2016. This tracer was not commercialised in our country until September 2016, so it was necessary to justify its use to obtain National Medicines Agency approval. We created a database which included: age, diagnose and reasons to justify 99mTc-Tektrotyd use, instead of 111 In-labelled SAT in imaging tests. Data were retrieved from electronic health records, including clinical history and nuclear medicine service requests.


32 requests were analysed: 28.125% of patients were <50 years old, 28.125% 50–70 years and 43.75% were older than 70 years. All patients had a NET diagnosis. The reasons for using the 99mTc-Tektroyd contrast were:


A 1 day imaging protocol, lower radiation and high resolution are the main reasons that justify the use of 99mTc-Tektrotyd in imaging tests for NET patients. The pharmacy and therapeutics committee will propose including 99mTc-Tektrotyd in our therapeutic arsenal for diagnose of NET in our centre.


No conflict of interest

Related Topics

    loading  Loading Related Articles